glp 1 causing pancreatitis GLP-1: Actions on Beta-cell Mass and Function Glucagon-like Peptide 1 Receptor Signaling

A small percentage of users report that the medication itself causes drowsiness, though this is not a documented side effect in major clinical trials

Caloric restriction, body image changes, and metabolic shifts during substantial weight reduction may affect neurotransmitter balance involved in mood regulation

For high-risk patients with complex conditions such as concomitant chronic kidney disease and liver diseases, there is currently a lack of sufficient evidence-based data to guide clinical decision-making

In the United States, prescribing information for all medications licensed for obesity that act on the CNS, including the GLP-1RAs liraglutide 3 mg (Saxenda) and semaglutide 2.4 mg (Wegovy), must include the recommendation of monitoring for depression and suicidal ideation 231

GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond PMC

Extensive preclinical studies have shown that incretin-based drugs can achieve significant cerebral protection and reduce neuronal loss by reducing synaptic loss and amyloid plaque load, decreasing hyperphosphorylation of proteins, and anti-inflammatory effects [54]